Analysts See $-0.45 EPS for Catabasis Pharmaceuticals (CATB); Hudson Global Has 1.18 Sentiment

Analysts expect Catabasis Pharmaceuticals Inc (NASDAQ:CATB) to report $-0.45 EPS on May, 11.They anticipate $0.16 EPS change or 26.23% from last quarter’s $-0.61 EPS. After having $-0.47 EPS previously, Catabasis Pharmaceuticals Inc’s analysts see -4.26% EPS growth. About 178,298 shares traded. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has declined 69.42% since September 27, 2016 and is downtrending. It has underperformed by 79.98% the S&P500.

Hudson Global, Inc. is a provider of professional-level recruitment and related talent solutions across the world. The company has market cap of $45.07 million. The Company’s divisions include Hudson Americas, Hudson Asia Pacific and Hudson Europe. It currently has negative earnings. The Company’s service offerings include Permanent Recruitment, Temporary Contracting, Recruitment Process Outsourcing (RPO) and Talent Management solutions.

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $27.04 million. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted , a linker drug discovery platform. It currently has negative earnings. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Among 3 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catabasis Pharmaceuticals had 5 analyst reports since August 17, 2015 according to SRatingsIntel. The rating was maintained by Citigroup with “Buy” on Thursday, June 9. Citigroup maintained it with “Buy” rating and $16 target in Tuesday, March 22 report. The company was maintained on Wednesday, June 8 by Wedbush. The stock has “Buy” rating by Wedbush on Monday, August 17. The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) earned “Buy” rating by H.C. Wainwright on Thursday, December 22.